Consideration of four socio-economic factors to set prices for essential HIV/AIDS product in multiple priority countries

Johnson & Johnson uses four socio-economic factors to set prices for essential HIV/AIDS products and targets 100% of priority countries relevant for this product. This is comparatively broad as the industry considers only two socio-economic factors and targets only 33% of relevant priority countries, on average.

Summary

  • What: Johnson & Johnson’s inter-country equitable pricing strategy for darunavir (Prezista®), considers four socio-economic factors to set prices for essential HIV/AIDS product in all priority countries.
  • Objective: The strategy aims to ensure affordability of this product in all corresponding priority countries.
  • Details: This relates to Johnson & Johnson’s product for HIV/AIDS, darunavir (Prezista®), in Ethiopia, India, Malawi, Mozambique, Nigeria, South Africa, Uganda and United Republic of Tanzania.
  • Socio-economic factors considered: (1) status of the pandemic, (2) the economic and health care situation of the country/region (3) cost, and (4) the availability of public financing.

 

Looking closer

Johnson & Johnson uses four socio-economic factors to set prices for essential HIV/AIDS product in all priority countries. For darunavir (Prezista®), which is on-patent and on the WHO Model Essential Medicines List (EML). Johnson & Johnson considers four socio-economic factors: status of the pandemic, the economic and health care situation of the country/region, cost and the availability of public financing. This inter-country equitable pricing strategy applies in all priority countries for HIV/AIDS. The 800mg daily dose of Prezista® is used in second-line regimens. It is offered at USD 36 per unit (USD 1.20 per patient per day ex-factory) in sub-Saharan Africa and in Least Developed Countries (for both public and private markets).

Sign up to receive updates about our work.